The Food and Drug Administration revealed that the Chinese firm Sinovac has applied for emergency use authorization (EUA).
FDA Chief Eric Domingo made the announcement after they gave the first EUA to Pfizer and BioNTech on the same day.
“Yesterday, nag-submit ng application ang Sinovac,” Domingo said during a virtual briefing.
Domingo added that Sinovac has yet to submit all the requirements for their EUA application.
“Ang naipadala pa lang nila ay ‘yung results ng Phase 1 and Phase 2 clinical trials. Until we see the results of Phase 3 clinical trials, hindi pa natin ma-a-asses iyong benefit at risk,” Domingo said.
Sinovac’s efficacy after human trials varied in different countries.
It registered a 50% efficacy in Brazil, 65% in Indonesia and 91% in Turkey. (TDT)